Introduction
Malignancy is a rare but well recognized cause of the nephrotic syndrome which was first described by Galloway (1922) . Various histopathological changes are described in the kidneys and these have been reviewed by Eagen & Lewis (1977) . Carcinoma is most frequently associated with membranous nephropathy and Hodgkin's disease with minimal change nephropathy (MCN). Lee et al. (1966) were the first to report a high incidence of carcinoma in patients presenting with the nephrotic syndrome: 11 of 104 nephrotic patients developed a carcinoma and 8 of those 11 had membranous nephropathy. The association was confirmed by Row et al. (1975) who found that 7 of 66 patients with membranous nephropathy also had occult carcinoma.
We present a patient who had a poorly differentiated carcinoma of the bronchus and MCN. The clinical events support the hypothesis that the tumour caused the renal lesion.
Case report
A 46 year old woman presented with a 3 month history of tiredness, cough, mild exertional dyspnoea and facial and peripheral oedema. She had smoked 10 cigerettes per day until 2 years before. Proteinuria was detected by her general practitioner, but her oedema had not responded to diuretic therapy and peripheral oedema was present on admission.
Laboratory investigations showed normal full blood count, urea, creatinine and electrolytes. Serum albumin was 20 g/l and selective proteinuria of 7.7 g/ 24 hours was demonstrated. A percutaneous renal biopsy contained 25 glomeruli with normal light microscopic appearances and no deposits of immunoglobulins, complement or fibrinogen by immunofluorescence. Electron microscopy demonstrated epithelial cell foot process fusion, but no other abnormality and a diagnosis of minimal change nephropathy was made. The chest X-ray revealed a left upper lobe opacity which was found to be due to an anaplastic bronchial carcinoma and a left upper lobectomy was performed.
The clinical course is summarized in Figure 1 . Postoperative proteinuria of 12.8 g/day fell to 0.4 g/day 3 weeks later. By the seventh post-operative week diuretics were discontinued. No steroid or immunosuppressive therapy was administered. During the next 15 months neither oedema nor proteinuria was detected, the serum albumin was normal and there was no evidence of tumour recurrence.
Nineteen months after surgery, mild peripheral oedema was noted and proteinuria of 13.4 g/day discovered. A chest X-ray revealed a left paramediastinal mass and mediastinoscopy and biopsy confirmed local recurrence of the original tumour. Diuretic therapy was commenced and local radiotherapy (45 Gy in 20 fractions) administered for 3 weeks. Six pulses of chemotherapy were given at monthly in- Despite resolution of the oedema, she remained unwell with continuing low levels of proteinuria. Persistence of tumour was detected on bronchoscopy. She subsequently developed a left hemiparesis and death occurred 3 years after initial presentation.
Discussion
The renal lesion in patients with nephrotic syndrome associated with carcinoma is most commonly membranous nephropathy. Eagen & Lewis (1977) found this lesion in 69% ofpatients with nephrotic syndrome and carcinoma. No particular type of carcinoma predominated and survival after tumour diagnosis was short (median 3 months), few patients having remission of their nephrotic syndrome. Others have reported that between 2 and 10% ofpatients with membranous nephropathy are subsequently found to have carcinoma (Row et al., 1975; Noel et al., 1979; Tu et al., 1984) . A few patients with carcinoma in association with proliferative, crescentic and membranoproliferative glomerulonephritis have also been reported (Hopper et al., 1975; Tydings et al., 1978; Jermanovich et al., 1982) .
Eagen & Lewis cited three cases of MCN associated with carcinoma in their 1977 review. However, only two of these have been published (Lee et al., 1966; Richard-Mendes da Costa et al., 1974) and in only the former is there detailed clinical and pathological information. Though the renal biopsy of this patient was examined by electron microscopy, the absence of immunofluorescence studies in either patient fails to fully exclude early membranous nephropathy (Helin et al., 1980; Pascal et al., 1976) . Three further patients have been reported (Moorthy, 1983; Forland & Bannayan, 1983 ) and the details of all five patients are shown in Table I . Two patients with small cell carcin- oma of bronchus showed partial tumour response and improvement in oedema following combination chemotherapy though significant proteinuria persisted until death. Interestingly the nephrotic syndrome in patient 4 had responded dramatically to prednisolone prior to tumour detection, but subsequently relapsed. The patient of Forland & Bannayan (1983) had only a minor improvement in his nephrotic syndrome following excision of the oncocytoma despite prednisolone therapy, though 2 years later complete resolution of his nephrotic syndrome occurred.
Deposition of immune complexes containing tumour associated and idiopathic MCN is, by contrast, obscure. Although Hodgkin's disease is the most cancer (Couser et al., 1974; Lewis et al., 1971; Wakashin et al., 1980; Weksler et al., 1974; Constanza et al., 1973) and the probable cause of proliferative lesions (Jermanovich et al., 1982) . The pathogenesis of both tumour associated and idiopathic MCN is, by contrast, obscure. Although Hodgkin's disease is the most commonly associated malignancy (Gagliano et al., 1976) , Plager & Stutzman (1971) found that only 4 out of 600 patients (0.65%) with Hodgkin's disease became nephrotic. However there is strong temporal evidence of a causal relationship. The diagnoses of nephrotic syndrome and Hodgkin's disease are often made at the same time and proteinuria remits only when the lymphoma is effectively treated and recurs when the tumour relapses (Plager & Stutzman, 1971; Ghosh & Muehrcke, 1970; Sherman et al., 1972) . These and other observations led Shalhoub (1974) to postulate that a soluble factor produced by lymphocytes was directly or indirectly toxic to the glomerular capillary and caused proteinuria. Some experimental support has been forthcoming (Lagrue et al., 1975; Boulton-Jones & Simpson, 1980; BoultonJones et al., 1983) , and relapses of MCN have been associated with pollen exposure (Reeves et al., 1975) , tuberculosis (Boulton-Jones, 1984) and circulating immune complexes (Levinsky et al., 1978) , all ofwhich may stimulate lymphokine production.
The patient reported here had the same temporal relationship between proteinuria and tumour activity as described in Hodgkin's disease. A causal relationship seems likely and the clinical course may provide clues to the pathogenesis. Remission followed tumour resection more quickly and completely than in previously reported cases, though neither steroids nor cytotoxic drugs were administered. This initial response and the recurrence ofproteinuria at the first sign of tumour recurrence are consistent with proteinuric factor production by or in response to the tumour. Moorthy (1983) postulated proteinuric factor production by the tumour in his two patients with small cell bronchial carcinoma, a tumour frequently associated with inappropriate hormone production. However, treatment ofthis patient's relapse by radiotherapy and chemotherapy led to remission of the proteinuria despite tumour progression. Although alternative explanations are possible, this dissociation may indicate that the proteinuric factor was not produced by the tumour cell but by another chemosensitive cell such as the T-lymphocyte.
